G
Gajanan N. Sapkal
Researcher at National Institute of Virology
Publications - 118
Citations - 3032
Gajanan N. Sapkal is an academic researcher from National Institute of Virology. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 24, co-authored 80 publications receiving 1616 citations. Previous affiliations of Gajanan N. Sapkal include Indian Council of Medical Research.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Raches Ella,Krishna Mohan Vadrevu,Harsh Jogdand,Sai Prasad,Siddharth Reddy,Vamshi Sarangi,Brunda Ganneru,Gajanan N. Sapkal,Pragya D Yadav,Priya Abraham,Samiran Panda,Nivedita Gupta,P. Prabhakar Reddy,Savita Verma,Sanjay K Rai,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Venkat Rao,Randeep Guleria,Krishna Murthy Ella,Balram Bhargava +23 more
TL;DR: A double-blind, multicentre, randomised, controlled phase 1 trial to assess the safety and immunogenicity of BBV152 at 11 hospitals across India is presented in this article.
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Raches Ella,Siddharth Reddy,Harsh Jogdand,Vamshi Sarangi,Brunda Ganneru,Sai Prasad,Dipankar Das,Dugyala Raju,Usha Praturi,Gajanan N. Sapkal,Pragya D Yadav,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Amit Bhate,Sanjay K Rai,Samiran Panda,Priya Abraham,Nivedita Gupta,Krishna Murthy Ella,Balram Bhargava,Krishna Mohan Vadrevu +25 more
TL;DR: In this article, the authors reported interim findings of the phase 2 trial on the immunogenicity and safety of BBV152, with the first dose administered on day 0 and the second dose on day 28.
Journal ArticleDOI
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees.
Pragya D Yadav,Gajanan N. Sapkal,Priya Abraham,Raches Ella,Gururaj Rao Deshpande,Deepak Y. Patil,Dimpal A Nyayanit,Nivedita Gupta,Rima R Sahay,Anita M. Shete,Samiran Panda,Balram Bhargava,V Krishna Mohan +12 more
TL;DR: In this paper, the authors used convalescent sera of COVID-19 cases and recipients of BBV152 (Covaxin) were able to neutralize VUI B.1.617.
Journal ArticleDOI
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020
Manoj V Murhekar,Tarun Bhatnagar,Sriram Selvaraju,Kiran Rade,V. Saravanakumar,Jeromie Wesley Vivian Thangaraj,Muthusamy Santhosh Kumar,Naman K. Shah,R. Sabarinathan,Alka Turuk,P. K. Anand,Smita Asthana,Rakesh Balachandar,Sampada Dipak Bangar,Avi Kumar Bansal,Jyothi Bhat,Debjit Chakraborty,Chethana Rangaraju,Vishal Chopra,Dasarathi Das,Alok Kumar Deb,Kangjam Rekha Devi,Gaurav Raj Dwivedi,S. Muhammad Salim Khan,Inaamul Haq,M. Sunil Kumar,Avula Laxmaiah,Madhuka,Amarendra Mahapatra,Anindya Mitra,A.R. Nirmala,Avinash Pagdhune,Mariya Amin Qurieshi,Tekumalla Ramarao,Seema Sahay,Y.K. Sharma,Marinaik Basavegowdanadoddi Shrinivasa,Vijay K. Shukla,Prashant Singh,Ankit Viramgami,Vimith Cheruvathoor Wilson,Rajiv Yadav,C. P. Girish Kumar,Hanna Elizabeth Luke,Uma Devi Ranganathan,Subash Babu,Krithikaa Sekar,Pragya D Yadav,Gajanan N. Sapkal,Aparup Das,Pradeep Das,Shanta Dutta,Rajkumar Hemalatha,Ashwani Kumar,Kanwar Narain,Somashekar Narasimhaiah,Samiran Panda,Sanghamitra Pati,Shripad A. Patil,Kamalesh Sarkar,Shalini Singh,Rajni Kant,Srikanth Tripathy,G S Toteja,Giridhara R Babu,Shashi Kant,J P Muliyil,Ravindra Mohan Pandey,Swarup Sarkar,Sujeet Kumar Singh,Sanjay Zodpey,Raman R. Gangakhedkar,Devarajulu Reddy,Balram Bhargava +73 more
TL;DR: Seroprevalence of SARS-CoV-2 was low among the adult population in India around the beginning of May 2020, and males, living in urban slums and occupation with high risk of exposure to potentially infected persons were associated with seropositivity.
Posted ContentDOI
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees
Pragya D Yadav,Gajanan N. Sapkal,Priya Abraham,Raches Ella,Gururaj Rao Deshpande,Deepak Y. Patil,Dimpal A Nyayanit,Nivedita Gupta,Rima R Sahay,Anita M. Shete,Samiran Panda,Balram Bhargava,V Krishna Mohan +12 more
TL;DR: In this paper, the authors used convalescent sera of COVID-19 cases and recipients of BBV152 (Covaxin) were able to neutralize VUI B.1.617.